Thieler Law Corp, member of the Investor Attorney Network, is investigating whether members of the board of directors of Dyax Corp (NASDAQ: DYAX) acted responsibly on behalf of investors’ profitability in the planned $5.4 billion sale to Shire plc (NASDAQ: SHPG).

On November 2, 2015, Dyax Corp (NASDAQ: DYAX) and Shire plc (NASDAQ: SHPG) announced that they had entered into a merger agreement. Under the terms of the merger agreement, Shire plc will offer Dyax Corp shareholders $37.30per share in cash for all outstanding shares. In addition, Dyax Corp shareholders may receive $4.00 in cash per Dyax share, upon clinical approval of DX-2930.

Based in Burlington, Massachusetts, and founded in 1989 Dyax Corp is a biopharmaceutical company focused on developing and commercializing therapeutics for patients with rare diseases.

The investigation focuses on whether NASDAQ: DYAX investors received the highest price and whether the directors of Dyax Corp acted in the best interest of Dyax Corp company and its shareholders.   

If you purchased Dyax Corp (NASDAQ: DYAX) prior to November 2, 2015, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185